LACTOLOGY FOUNDATION

Laxatives (ATC A06) are drugs for constipation that act via different mechanisms in the intestinal lumen and wall, with generally favourable lactation safety when used appropriately and for clear indications.medpedia.framar+3

Pharmacological class and mechanisms

ATC A06 “Drugs for constipation” is a therapeutic subgroup within the anatomical group A “Alimentary tract and metabolism”. It comprises all medicinal agents used to treat constipation, independent of the underlying indication.wikipedia+4

On the Bulgarian source page, laxatives are described as medicines used in patients with constipation, defined clinically by fewer than three bowel movements per week and difficult, often painful defecation, particularly frequent in older adults and pregnant women. When dietary measures fail, pharmacological laxatives are introduced, with key mechanistic groups including osmotic laxatives that retain water in the intestinal lumen, contact (stimulant) laxatives that enhance intestinal motility, and faecal softeners that soften stool consistency.drugoffice+3

Typical pharmacological subclasses within A06A include: stool softeners and emollients (such as liquid paraffin, docusate), contact or stimulant laxatives (bisacodyl, senna glycosides, sodium picosulfate, castor oil), bulk‑forming laxatives (dietary fibre, ispaghula/psyllium, methylcellulose), osmotically acting laxatives (such as magnesium salts, lactulose, macrogols), and other agents (including peripheral opioid antagonists for opioid‑induced constipation).atcddd.fhi+6

Indications and clinical use

Laxatives are indicated for symptomatic treatment of constipation of various aetiologies, after optimisation of non‑pharmacological measures such as increased dietary fibre, fluid intake, and physical activity. They are also used in specific situations such as bowel preparation, management of constipation secondary to medications (notably opioids), and in conditions where straining should be minimised (for example certain cardiovascular or anorectal disorders).breastfeedingnetwork+3

The Bulgarian text emphasises that constipation is particularly prevalent among older adults and pregnant women, and that diet is the primary approach, with laxatives reserved for insufficient response. Product listings on the same page illustrate the breadth of pharmaceutical forms and active substances in this class, such as macrogol‑containing sachets, castor oil, bisacodyl tablets, liquid paraffin, glycerol, magnesium sulphate, and lactulose‑ or macrogol‑based syrups.naver+4

General toxicological profile

The toxicological profile of A06 drugs is strongly mechanism‑dependent. Bulk‑forming agents are minimally absorbed and have a wide safety margin; their main risks are bloating, flatulence, and, if taken with insufficient fluids or in patients with structural bowel disease, rare obstruction. Osmotic laxatives (for example lactulose, macrogols, magnesium salts) can cause abdominal distension, cramping, and diarrhoea; in high doses or in patients with renal impairment, magnesium‑containing products may provoke electrolyte disturbances.atcddd.fhi+3

Stimulant laxatives (bisacodyl, senna glycosides, cascara, sodium picosulfate, castor oil) act on enteric nerves and fluid secretion, and can produce colicky abdominal pain, abrupt diarrhoea, and, if overused, dehydration and electrolyte imbalance. Long‑term, unsupervised use of stimulants is associated with tolerance, dependence on laxatives for bowel movements, and potential melanosis coli; therefore, guidelines recommend restricting them to short‑term or intermittent use. Liquid paraffin and related emollients may impair absorption of fat‑soluble vitamins if used chronically, and aspiration risk is a concern in frail or bedridden patients.atccode+4

At the class level, serious acute toxicity most often reflects misuse: large doses, prolonged daily use, unsupervised polypharmacy, or use in patients with undiagnosed abdominal pain, obstruction, or severe inflammatory bowel disease. Toxicological precautions therefore include limiting duration without medical review, avoiding in suspected obstruction, carefully assessing comorbidities and concomitant medications, and monitoring fluids and electrolytes in high‑risk patients (elderly, renal or cardiac impairment).ncbi.nlm.nih+2

Lactation safety considerations

For breastfeeding, current expert sources state that essentially all standard laxatives can be used, as most are poorly absorbed from the gastrointestinal tract and hence pass into breast milk in negligible amounts. Osmotic laxatives such as lactulose, macrogols, and magnesium salts show very low passage into breast milk and are considered compatible with breastfeeding; these are preferred initial choices when pharmacological treatment of constipation is required in nursing mothers.sps+1

Bulk‑forming laxatives (for example psyllium, polycarbophil) are not systemically absorbed and are likewise regarded as safe for use during breastfeeding, without expected effects on the infant. Stimulant laxatives (senna, bisacodyl, sodium picosulfate) can be used for short courses; systemic exposure in the mother is limited and only small amounts, if any, pass into milk, though some guidelines suggest reserving them for second‑line use because theoretical infant effects (looser stools, cramping) cannot be completely excluded.mayoclinic+2

An NHS specialist source notes that any conventional laxative may be used in breastfeeding, with caution advised for prucalopride due to detectable, albeit low, breast‑milk levels. Across the class, monitoring of the breastfed infant for changes in stool frequency or consistency, irritability, or poor weight gain is prudent when a new laxative is started or doses are increased. In line with lactation‑pharmacology principles, non‑pharmacological measures should still be optimised first, and the lowest effective dose and shortest effective course of medication should be used.medpedia.framar+2

Pregnancy and peripartum safety

Constipation is common in pregnancy, and stool softeners and bulk‑forming agents are generally considered safe in this context because they are minimally or not absorbed systemically. Clinical guidance from obstetric sources indicates that docusate stool softeners and bulk‑forming laxatives (psyllium, polycarbophil) are unlikely to harm the developing fetus when used at recommended doses, and that certain osmotic and stimulant laxatives (such as magnesium hydroxide, magnesium citrate, bisacodyl, and lactulose) can also be used on a short‑term basis after medical consultation.breastfeedingnetwork+2

The Bulgarian page notes that constipation is especially frequent in pregnant women, again emphasising dietary and lifestyle interventions as first‑line. Toxicologically, the peripartum period requires heightened attention to fluid balance, haemodynamics, and avoidance of severe diarrhoea or electrolyte shifts; as a result, chronic high‑dose stimulant laxative regimens are discouraged in pregnancy and immediately postpartum. Individual drug selection in pregnant and breastfeeding women should follow up‑to‑date obstetric and hepatogastroenterology recommendations, with preference for agents with the most reassuring human data.drugoffice+5